EUVIMEDEUVIMED entdecken
Crossref

First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells

Joopyoung Kim, Han Inbo, Hyun Sook Kim, WonChan Kim, Su Jin Jang, Kyunghoon Min, Sang Heum Kim, Sang-Hun Bae, Yun-Hwa Jeong, Borah Kim, Chul Kim, Sigrid C Schwarz und 4 weitere

Movement Disorders · 2023

DOI: 10.1002/mds.29316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2023. Verfasst von Joopyoung Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Neural Stem Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Because human fetal ventral mesencephalic tissue grafts provide promising results in ameliorating Parkinson's disease–implicated motor dysfunctions, human fetal midbrain‐derived dopamine neuronal precursor cells are considered good candidates for cell‐based therapy for Parkinson's disease in that large quantities of cells can be supplied through a good manufacturing practice–compliant system.

Objective

We conducted a prospective, phase I/IIa, dose‐escalation, open‐label “first‐in‐human” clinical trial with fetal neural precursor cells to assess their safety and therapeutic efficacy in patients with idiopathic Parkinson's disease.

Methods

Fifteen patients were assigned to receive three different doses of cells (4 × 10 6 , 12 × 10 6 , and 40 × 10 6 cells) and completed a 12‐month follow‐up. The primary outcome was safety, by measuring the presence of grade 3 or higher cells according to National Cancer Institute guidelines and any contaminated cells. Secondary outcomes assessed motor and neurocognitive function, as well as the level of dopamine transporters, by positron emission tomography–computed tomography.

Results

Although a pronation‐supination and hand/arm movement performance was remarkably enhanced in all three groups (all P < 0.05), the medium‐ and high‐dose‐treated groups exhibited significant improvement in Unified Parkinson's Disease Rating Scale Part III only up to 26.16% and 40%, respectively, at 12 months after transplantation without any serious clinical complications or graft‐induced dyskinesia in all patients. However, the motor improvements did not correlate with increase in the dopamine transporter on positron emission tomography images.

Conclusions

Our results primarily demonstrate the safety and plausible dose‐dependent efficacy of human fetal midbrain‐derived dopamine neuronal precursor cells for idiopathic Parkinson's disease. © 2023 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseNeural Stem CellsHumansDopamineProspective StudiesTomography, X-Ray ComputedMesencephalon

Stichwörter der Autor:innen

Parkinson's diseaseclinical trialefficacyhuman fetal mesencephalic dopamine neural precursor cellssafety

Substanzen

Dopamine

Autor:innen und Institutionen

  • Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Neuroradiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
  • Department of Biotechnology, CHA University, Seongnam, Republic of Korea.

ORCID-Profile: Jisook Moon

Zitieren

APA

Kim, J., Inbo, H., Kim, H. S., Kim, W., Jang, S. J., Min, K., Kim, S. H., Bae, S. H., Jeong, Y. H., Kim, B., Kim, C., Schwarz, S. C., Schwarz, J., Cho, K. G., Chung, S. S., & Moon, J. (2023). First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Movement Disorders. https://doi.org/10.1002/mds.29316

Vancouver

Kim J, Inbo H, Kim HS, Kim W, Jang SJ, Min K, et al. First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Movement Disorders. 2023. doi:10.1002/mds.29316

BibTeX
@article{Kim2023,
  author = {Kim, Joopyoung and Inbo, Han and Kim, Hyun Sook and Kim, WonChan and Jang, Su Jin and Min, Kyunghoon and Kim, Sang Heum and Bae, Sang-Hun and Jeong, Yun-Hwa and Kim, Borah and Kim, Chul and Schwarz, Sigrid C and Schwarz, Johannes and Cho, Kyung Gi and Chung, Sang-Sup and Moon, Jisook},
  title = {First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells},
  journal = {Movement Disorders},
  year = {2023},
  doi = {10.1002/mds.29316}
}
Kostenlos starten →